1. Disparities in speed to BMT consult and allograft in 279 adults with AML
- Author
-
Warren Benjamin Fingrut, Boglarka Gyurkocza, Eric Davis, Jessica Flynn, Andromachi Scaradavou, Stephanie Chinapen, Kristine Naputo, Sean Quach, Christina Cho, Sergio Giralt, Esperanza Bouza Papadopoulos, Miguel-Angel Perales, Brian C. Shaffer, Ioannis Politikos, and Juliet Naomi Barker
- Subjects
Cancer Research ,Oncology - Abstract
6523 Background: Whether patient (pt) ancestry impacts the time to BMT is not established. Methods: We hypothesized that non-European (non-EURO) ancestry AML pts are at increased risk of delayed time to transplant. Thus, we analyzed time to allograft (Allo) by ancestry defining delayed (late) times as: Allo Indication to BMT Consult (Ind. – Consult) > 90 days, Consult – BMT > 120 days & Allo Indication to BMT (Ind. - BMT) > 180 days. We studied pts < 70 yrs transplanted 1/2016-7/2021. Results: In 279 AML pts (median 56 yrs, range 19-69), BMT indication was date of diagnosis if ELN 2017 intermediate/ high risk &/or high risk mutations &/or sAML in 261 (94%) pts, or date of refractory/ relapsed disease in 18 (6%) pts. European (EURO) pts (n = 195, 70%; median 60 yrs) were older than non-EURO pts (n = 84, 30%; median 49 yrs), p
- Published
- 2022
- Full Text
- View/download PDF